Kobe University · University Hospital · 准教授

Research keywordschronic pain・fibromyalgia・microglia・HMGB1・neuropathic pain・general anesthetics・perioperative analgesia・postoperative hyponatremia

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Subtype-specific modulation of inhibitory interneurons by general anesthetics2026 · Elsevier BV, 2026年03月, iScience, 29(3) (3), 115140 - 115140
• Improvement of sleep and pain with lemborexant administration in patients with chronic pain: a retrospective observational study.2021 · OBJECTIVE: Patients with chronic pain often have sleep disturbances, and many patients receive sleep medications in addition to analgesics. Although there have been scattered reports of negative pain-sleep interactions, only a few reports have investigated the efficacy of sleep medication interventions in patients with chronic pain for improving sleep disturbances and reducing pain. We retrospectively examined whether lemborexant, an orexin receptor antagonist, is effective in improving sleep disturbances and reducing pain in patients with chronic pain. This study was approved by the Ethics Committee of our hospital. METHODS: The subjects were 26 patients with chronic pain undergoing treatment at our pain clinic between July 2021 and March 2022, who had been diagnosed with insomnia, with an Athens Insomnia Scale (AIS) score of ≥6 and had been started on lemborexant. The AIS score and pain score (Numeric Rating Scale [NRS]) before and after 2 and 4 weeks of starting lemborexant were investigated. RESULTS: Patients who were already taking other sleep medications, such as benzodiazepines were switched to 5 mg of lemborexant after all the other sleep medications were discontinued. Those who had not yet used sleeping pills were started on 5 mg of lemborexant. During the study course, the dose of lemborexant was adjusted at the discretion of the attending physician, based on improvement of insomnia symptoms and secondary symptoms, such as daytime sleepiness and lightheadedness. The study finally included 21 patients, excluding 5 who could not continue taking lemborexant due to side effects, such as lightheadedness. The AIS scores significantly improved, decreasing from baseline (mean ± standard deviation: 12.5 ± 4.9) to 2 weeks (7.8 ± 3.1) and 4 weeks (5.3 ± 2.9) after the start of lemborexant. No significant difference was observed in the degree of improvement in sleep disturbance between patients with or without previous sleep medications, and there was also no statistically significant improvement in the NRS score before (6.1 ± 2.7) and after 2 weeks (5.5 ± 2.3) and 4 weeks (5.9 ± 2.2) from treatment initiation.
• Sex-dependent role of microglia in disulfide high mobility group box 1 protein-mediated mechanical hypersensitivity2021 · Ovid Technologies (Wolters Kluwer Health), 2021年02月, Pain, 162(2) (2), 446 - 458
• Passive transfer of fibromyalgia symptoms from patients to mice2021 · American Society for Clinical Investigation, 2021年07月, Journal of Clinical Investigation, 131(13) (13)

• ミトコンドリア分裂因子Drp1に着目した神経障害性疼痛のメカニズム解明 坪井 ちづ, 野村 有紀 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2025年04月01日 - 2028年03月31日2025 · KUID parsed section
• サテライトグリア細胞のミトコンドリア機能に着目した線維筋痛症の病態解明 野村 有紀 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2024年04月01日 - 2027年03月31日2024 · KUID parsed section
• 免疫細胞のオピオイド受容体活性化に着目した疼痛慢性化メカニズムの解明 西原 侑紀, 野村 有紀, 佐藤 仁昭 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2024年04月01日 - 2027年03月31日2024 · KUID parsed section
• 副作用のない麻酔薬の開発を目的としたアセチルコリン受容体の分子構造解析 田口 真也, 野村 有紀, 溝渕 知司 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2023年04月 - 2026年03月, 研究分担者2023 · KUID parsed section

• Official profile